Harbeck, N <br/><br/>
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Sep 2001 
 - 2757-64 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--drug therapy<br/>Cathepsin B--analysis<br/>Cathepsin D--analysis<br/>Cathepsin L<br/>Cathepsins--analysis<br/>Chemotherapy, Adjuvant<br/>Cysteine Endopeptidases<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoassay<br/>Middle Aged<br/>Multivariate Analysis<br/>Plasminogen Activator Inhibitor 1--analysis<br/>Prognosis<br/>Survival Analysis<br/>Time Factors<br/>Treatment Outcome<br/>Urokinase-Type Plasminogen Activator--analysis